Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

@article{Voorhees2009TargetedIO,
  title={Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.},
  author={Peter Michael Voorhees and Qing Chen and George W Small and Deborah J. Kuhn and Sally Anne Hunsucker and Jeffrey A. Nemeth and Robert Z. Orlowski},
  journal={British journal of haematology},
  year={2009},
  volume={145 4},
  pages={481-90}
}
Interleukin (IL)-6-mediated signalling attenuates the anti-myeloma activity of glucocorticoids (GCs). We therefore sought to evaluate whether CNTO 328, an anti-IL-6 monoclonal antibody in clinical development, could enhance the apoptotic activity of dexamethasone (dex) in pre-clinical models of myeloma. CNTO 328 potently increased the cytotoxicity of dex in IL-6-dependent and -independent human myeloma cell lines (HMCLs), including a bortezomib-resistant HMCL. Isobologram analysis revealed that… CONTINUE READING